Systems Biology Opens the Blackest Boxes
Systems Biologists Are Attacking the Encrypted Messages That Would Allow Us to Predict and Change the Course of Disease
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Fast forwarding to the near future and based on the recent past, sequencing instrument companies will continue to develop more user-friendly and cheaper technology, focused on the benchtop and clinical markets. On a worldwide basis, research, discovery, and development applications comprise the two largest sequencing markets. By far the largest market opportunity, though, is in personal genomics and clinical diagnostics. These segments are expected to reach $541 million by 2015 from $15.5 million in 2010. Recent advancements in the field of next-generation sequencing have resulted in the advent of so-called personal genome machines. Companies aiming at the clinical space will need to gain regulatory approval for their use in clinical laboratory diagnostics. What do you think this year holds for sequencing technologies in the clinical space?